Results 181 to 190 of about 3,628 (221)
Some of the next articles are maybe not open access.
Use of Cangrelor in Older Patients: Findings from the itAlian pRospective Study on CANGrELOr Study
The American Journal of CardiologyOutcome data on using cangrelor in older patients are limited. This post hoc analysis of the itAlian pRospective Study on CANGrELOr (ARCANGELO) study aims to assess bleeding and ischemic outcomes with the transition from cangrelor to any oral P2Y12 inhibitors in age-stratified subgroups (≥75 years-older,
Capranzano, Piera +13 more
openaire +3 more sources
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, 2023Francesco Franchi +2 more
exaly
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor
JACC: Cardiovascular Interventions, 2023Francesco Franchi +2 more
exaly
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention
American Heart Journal, 2021Charan Yerasi +2 more
exaly